Midland Florida Clinical Research Center, LLC | DeLand, FL

Research site

(Unclaimed)

Location

665 Peachwood Drive, DeLand, Florida, United States of America

Site insights

Top conditions

Top treatments

Lenacapavir

Bictegravir

Emtricitabine

TAF

Tenofovir Alafenamide

Enobosarm

GTx-024

GS-1720

Elagolix

GS-3242

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 36 total trials

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2)

The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.

Active, not recruiting

Crohn's Disease

Drug: Mirikizumab

A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL

The purpose of this clinical evaluation is to collect patient outcome data and evaluate the efficacy, safety and tolerability of HealthTech DermaBind...

Enrolling

Venous Leg Ulcer (VLU)

Diabetic Foot Ulcer (DFU)

Biological: DermaBind TL

A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1

The study will have two parts: Part A and Part B. In Part A, the goal of the study is to compare the effectiveness of switching to the study drugs GS...

Enrolling

HIV-1-infection

Drug: Lenacapavir Injection

Drug: GS-3242 Injection

A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

The goal of this study is to test the effectiveness, safety, and tolerability of the combination of broadly neutralizing antibodies (bNAbs) (teropavi...

Active, not recruiting

HIV-1 Infection

Drug: Lenacapavir Injection

Drug: Lenacapavir Tablet

Locations recently updated

Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

The goal of this clinical study is to compare how effective a long-acting injectable treatment of lenacapavir (LEN), teropavimab (TAB), and zinlirvim...

Enrolling

HIV Infections

Drug: Cabotegravir

Drug: Teropavimab

Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed (WONDERS1)

The goal of this clinical study is to learn more about the experimental drugs lepetegravir and lenacapavir pacfosacil; to compare the combination of...

Active, not recruiting

HIV-1-Infection

Drug: Lepetegravir

Drug: Lepetegravir/Lenacapavir pacfosacil FDC

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus...

Active, not recruiting

HIV-1-infection

Drug: Stable Baseline Regimen

Drug: Bictegravir

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (CAPELLA)

The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing re...

Active, not recruiting

HIV-1-infection

Drug: Optimized Background Regimen (OBR)

Drug: Oral Lenacapavir Placebo

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms